HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.